Clinical Trials

Congenital Adrenal Hyperplasia

Neurocrine Biosciences has completed a Phase I investigational new drug (IND)-opening study of NBI-74788 in healthy volunteers. The study was a randomized, open-label, two-period crossover study to evaluate the pharmacokinetics and safety of NBI-74788 in a total of 16 adults.

Neurocrine Biosciences is conducting a Phase II proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NBI-74788 in adult patients with classic congenital adrenal hyperplasia (CAH). The interim results from this ongoing open-label, multiple-dose, dose-escalation study were reported in March 2019. For more information on this Phase II study of NBI-74788 in CAH (CAHlibrate), please visit www.cahlibratestudy.com.

Neurocrine Biosciences is conducting a Phase II, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-74788 in pediatric female and male patients (14 to 17 years of age) with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). For more information on this Phase II study of NBI-74788 in pediatric patients with CAH (CAHlibrate Pediatric Study), please visit CAHlibratePediatricStudy.com or clinicaltrials.gov.